US Pharma MarketingThe cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that way
Priority review voucher prices have roughly doubled in recent years, with 2026 sales hitting $180 million to $205 million. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo…
How much is a regulatory shortcut worth?
The cost of a priority review voucher, which shortens the FDA’s standard review time by about four months, has roughly doubled in the last few years. The FDA ...
Source: Endpoints News